Summary The International Initiative on Thrombosis and Cancer is an independent
academic working group of experts aimed at establishing global consensus for the treatment …

Patients with cancer are prone to develop venous thromboembolism (VTE) that is the
second leading cause of mortality among them. Cancer patients with VTE may encounter …

Objectives This study investigated the treatment pattern and the rate of bleeding
complications in real-world practice in cancer-associated venous thromboembolism (CT) …

Background The use of direct oral anticoagulants (DOACs) as an alternative to low-
molecular-weight heparin (LMWH) for extended thromboprophylaxis of abdominal/pelvic …

Venous thromboembolism is a leading cause of morbidity and mortality in patients with
active cancer who require anticoagulation treatment. Choice of anticoagulant is based on …

Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in patients
with cancer. On the basis of results from randomized controlled trials, direct oral …

Cancer-associated thrombosis (CAT) poses a significant disease burden and the incidence
in Asian populations is increasing. Anticoagulation is the cornerstone of treatment, but can …

Background Meta‐analyses are widely used to strengthen available evidence and obtain
more precise estimates of treatment effect than any individual trial. Paradoxically …

Background To evaluate the efficacy and safety of different direct oral anticoagulants
(DOACs) compared with low molecular weight heparins (LMWHs) in the treatment of venous …

Patients with active cancer are at high risk of recurrent venous thromboembolism (VTE).
Usual treatment includes low molecular weight heparin (LMWH), while vitamin K antagonists …